CALQUENCE® (acalabrutinib) Clinical Insights from a Real-World Patient with Treatment Naive CLL
27:13
Dr Daniel Landau Presents CALQUENCE Long-Term and Pooled Cardiovascular Safety Data for CLL/SLL
1:08:05
A Patient Story
22:04
CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD
4:48
CALQUENCE® (acalabrutinib) Patient Testimonials: Emil's Story
20:01
CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD
12:20
CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD
9:28
CALQUENCE® (acalabrutinib) Perspectives: Dr Andre Goy, MD
15:59